NCT00000642View on ClinicalTrials.gov

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

Not specified

Conditions

HIV InfectionsPregnancy

Interventions

DRUG

CD4-IgG

Trial Locations (2)

11203

SUNY - Brooklyn, Brooklyn

77030

Texas Children's Hosp / Baylor Univ, Houston

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000642 - A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns | Biotech Hunter | Biotech Hunter